Cancer prevention
Cancer is a vast and complex group of common diseases (400,000 cases in France, 4 million in the EU) whose nosological classification is rapidly evolving alongside molecular and immunological categorizations. Many cancers remain incurable despite the advent of precision medicine. Paradigm shifts are therefore required for most cancers, necessitating a more advanced understanding of the biological drivers of progression, refined prevention strategies, and a better grasp of exogenous risk factors. Many treatments now require comprehensive molecular and immunological analysis of cells, accounting for their spatial and temporal evolution. These are the challenges that citizens, patients, healthcare professionals, and researchers will need to address in the coming years. Connecting these components is the goal of the SHAPE-Med@Lyon oncology program.
Lyon is uniquely positioned to develop this program, hosting a vast array of cutting-edge expertise, scientific output, and oncology education programs—including over 1,300 high-impact annual publications (representing 15% of France’s total)—as well as the CRCL (France’s dedicated cancer research center), IARC/WHO, VetAgro Sup, and expert clinical research teams at the CLB and HCL. With leadership spanning basic, epidemiological, clinical, and human and social sciences, Lyon’s track record of excellence also encompasses the AURAGEN WGS sequencing platform, SIRIC LYRICAN, LabEx DEVweCAN, and the European Reference Networks (ERNs) EURACAN and Cancer Prevention Europe (CPE).
Workshop facilitators
Frédérique Ponce
Deputy Director General, VetAgroSup – Professor of Comparative Oncology – Campus Vétérinaire de Lyon
Marie Préau
University Professor, Université Lumière Lyon 2; Director, Inserm Unit 1290
Funded projects
Seed Funding projects — 24 months
Structuring projects — 48 months
From cultivated biodiversity to human health prevention: a research action project in Lyon’s area.
Marie-Thérèse CHARREYRE | IMP
Florence CARROUEL | P2S
Description of the neurocognitive and psychiatric
disorders associated with targeted therapies
used in the treatment of lung cancers.
Myriam PANNARD | PôPS
Michael DURUISSEAUX | CRCL, HCL
Investigation of a predictive therapeutic response under controlled oxygen condition in cancer patient-derived organoids.
Nicolas AZNAR | CRCL
Jean-Paul RIEU | ILM
Evaluation of the impact of exposure to pollution (traffic related air pollutant) on the overall survival of aml patients treated in haematology departments in the AURA region.
Thomas COUDON | Défense, Santé, Environnement
Amine BELHABRI | CRCL /HCL
Implementing optogenetic and 3D tumor-on-chip model to characterize cancer immunogenic cell death by pyroptosis.
Virginie PETRILLI | CRCL
Charlotte RIVIÈRE | ILM
Transdisciplinary approach to acute aerobic
exercise concomitant to chemotherapy in
metastatic colorectal cancer: tumor effetcs,
clinical, sociological and territorial implications.
Béatrice FERVERS | CLB
Claire PERRIN | L-VIS
Standard and innovative endometrial cancer therapy evaluation on an original and mechanically relevant 3D model of organ-on chip.
Stefan CATHELINE | LabTAU
Isabelle RAY-COQUARD | RESHAPE-CLB
Immunotherapy and nanomedicine to overcome drug resistance in peritoneal carcinosis.
David KRYZA | LAGEPP-HCL
Frédérique PONCE | VetAgro Sup
Define the role of mitochondria in adaptative
cancer cell motility.
Gabriel ICHIM | CRCL
David COULETTE | UMPA ENS Lyon
Multi-omics data integration to investigate
biological mechanisms underlying the link
between lifestyle behaviors and gastro-intestinal cancers.
Vivian VIALLON | CIRC
Yohann DE CASTRO | Institut Camille Jordan
Combined neuropsychological and neurohepatological approaches for studying the evolution towards hepatocarcinoma.
Emilie FAVRE | EMC
Romain PARENT | CRCL